Keywords: Vivus, Topiramate, Qnexa, Obesity, Birth defects
Vivus findings show greater risk of birth defects with Qnexa ingredient
Article | 23 December 2011
USA-based drug developer Vivus (Nasdaq: VVUS) has released top-line preliminary results from its retrospective study of medical claims data on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
